Site icon pharmaceutical daily

$6.5+ Billion MRD (Minimal Residual Disease) Testing Market – Global and Regional Analysis and Forecasts to 2033 – Revolutionary Technologies Transform MRD Testing Market for Cancer Patients – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “MRD Testing Market – Global and Regional Analysis: Focus on Technology, Target Detection, End User and Region Analysis – Analysis and Forecast, 2023-2033” report has been added to ResearchAndMarkets.com’s offering.


The global MRD testing market is projected to reach $6.67 billion by 2033 from $1.47 billion in 2022, growing at a CAGR of 14.81% during the forecast period 2023-2033.

The MRD testing market is driven by several factors, including the expansion in medicare coverage for MRD testing and the administration of solid tumor diagnosis. In recent years, as consumer awareness has grown, there has been an increasing demand for MRD testing. Healthcare providers and researchers are recognizing this trend and striving to meet the expectations of patients by integrating MRD testing into clinical practice.

The global MRD testing market is a rapidly growing segment in the healthcare industry, driven by the increasing demand for accurate and sensitive methods to monitor and manage cancer patients. This market focuses on technologies such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and flow cytometry that enable the detection and quantification of minimal residual disease (MRD) in cancer patients.

With its clinical significance in treatment response monitoring, prognostic assessment, and personalized treatment approaches, the minimal residual testing market offers immense opportunities for diagnostic companies, pharmaceutical manufacturers, and research institutions to develop innovative solutions and contribute to improving patient outcomes and survival rates.

Furthermore, the rising incidence of cancer has spurred research and technological advancements in the field of MRD testing. Efforts to enhance the sensitivity, accuracy, and efficiency of MRD testing methods have been driven by the need to address the diagnostic challenges posed by increasing cancer rates. These aforementioned advancements in minimal residual disease testing have resulted in the development of new technologies, improved laboratory protocols, and novel approaches.

Market Segmentation

Flow Cytometry to Continue its Dominance as Leading Technology Segment

The global MRD testing market is led by flow cytometry in the technology segment, with a 41.14% share in 2022. The market growth is attributed to recent technological innovations in multiparametric flow cytometry, such as the development of high-sensitivity 10-color and 12-color flow cytometry assay for the identification of leukemia-associated phenotypes (LAPs) and estimation of the prognostic significance of treatment in MRD patients.

MRD testing uses highly sensitive methods such as flow cytometry, PCR, NGS, and other methods. These tests use bone marrow samples and/or peripheral blood cells (taken through a vein). Significant advancements are being witnessed in the development of highly sensitive, quantitative, and multiplex assays.

Some of the new technologies include NGS and low-cost PCR devices available in the form of multiparameter assays and multiplexing devices for MRD testing. Techniques such as karyotyping and classical microscopy have lesser value in MRD detection due to their low sensitivity.

Solid Tumor-Based Target Detection to Witness the Highest Growth between 2023 and 2033

The global MRD testing market is estimated to be led by the solid tumor in the target detection segment, with a share of 15.09% in 2022, owing to the increasing number of companies entering the market with a focus on solid tumor based MRD testing. The assessment of minimal residual disease (MRD) is a crucial prognostic indicator, and the application of circulating tumor DNA (ctDNA) analysis for evaluating MRD in solid tumors after curative treatment and prior to disease recurrence has shown great therapeutic potential. This promising advancement is a key driving force behind the growth of ctDNA analysis in the field.

Hospitals and Speciality Clinics to Witness the Highest Growth between 2023 and 2033

The global MRD testing market is estimated to be led by the hospitals and specialty clinics in the end user segment, with a share of 44.38% in 2022. Hospitals are at the forefront of providing MRD testing kits and services to detect residual cells in solid tumors and hematological malignancies in routine healthcare procedures. There is high adoption of various testing assays by hospitals, particularly in the field of oncology.

Moreover, hospitals, particularly in leading regions such as North America and Europe, and also to a certain extent in Asia-Pacific (APAC), have incorporated extensive molecular diagnostics test portfolios to provide superior care to patients. Other end users, such as outpatient clinics and cancer clinics, also contribute significantly to the global MRD testing market.

Regional Analysis

North America’s minimal residual disease testing market is expected to reach $2.75 billion in 2033 and is currently the leading contributor to the market.

The rising incidence of hematological malignancies such as leukemia and lymphoma, coupled with the development of innovative tests, are key factors that contribute to North America’s dominance in the global MRD testing market. However, the Asia-Pacific region, constituting several emerging economies, is expected to register the highest CAGR of 16.06% during the forecast period 2023-2033.

Competitive Strategies

Key players in the MRD testing market analyzed and profiled in the study involve major residual testing-based companies and test manufacturers.

Moreover, a detailed competitive benchmarking of the players operating in the MRD testing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

The top segment players leading in the market include 11 public companies that capture around 73.33% of the presence in the market. On the other hand, there are four private players, including Invivoscribe, Inc. and Mission Bio, among others, which account for approximately 26.67% of the presence in the market.

Recent Developments in the MRD Testing Market

Key Companies Profiled:

Market Dynamics

Market Drivers

Market Challenges

Market Opportunities

Industry Insights

Legal and Regulatory Framework of MRD Tests

Reimbursement Scenario

Supply Chain Analysis

Market Overview

For more information about this report visit https://www.researchandmarkets.com/r/mwi5br

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Exit mobile version